

This is a repository copy of *Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors*.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/156192/

Version: Accepted Version

Article:

Vidilaseris, K, Johansson, NG, Turku, A et al. (5 more authors) (2019) Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors. Journal of Visualized Experiments, 153. e60619. ISSN 1940-087X

https://doi.org/10.3791/60619

© 2019 Journal of Visualized Experiments. This is an author produced version of a paper published in Journal of Visualized Experiments. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/

TITLE:

Screening for Thermotoga Maritima Membrane-Bound Pyrophosphatase Inhibitors

AUTHORS AND AFFILIATIONS:

Keni Vidilaseris^{1,*}, Niklas G. Johansson^{2,*}, Ainoleena Turku², Alexandros Kiriazis², Gustav Boije af Gennäs², Jari Yli-Kauhaluoma², Henri Xhaard², Adrian Goldman^{1,3}

¹Research Program in Molecular and Integrative Biosciences, University of Helsinki, Helsinki, Finland

²Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland

³School of Biomedical Sciences and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK

*These authors contributed equally.

Email addresses of co-authors:

Keni Vidilaseris	(keni.vidilaseris@helsinki.fi)
Niklas G. Johansson	(niklas.johansson@helsinki.fi)
Ainoleena Turku	(ainoleena.turku@gmail.com)
Alexandros Kiriazis	(alexandros.kiriazis@helsinki.fi)
Gustav Boije af Gennäs	(gustav.boije-afgennas@helsinki.fi)
Jari Yli-Kauhaluoma	(jari.yli-kauhaluoma@helsinki.fi)
Henri Xhaard	(henri.xhaard@helsinki.fi)

Corresponding author:	
Adrian Goldman	(a.goldman@leeds.ac.uk)

KEYWORDS:

membrane-bound pyrophosphatase, *Thermotoga maritima*, inhibitor screening, molybdenum blue reaction, protist diseases, drug design

SUMMARY:

Here we present a screening method for membrane-bound pyrophosphatase (from *Thermotoga maritima*) inhibitors based on the molybdenum blue reaction in a 96 well plate format.

ABSTRACT:

Membrane-bound pyrophosphatases (mPPases) are dimeric enzymes that occur in bacteria, archaea, plants, and protist parasites. These proteins cleave pyrophosphate into two orthophosphate molecules, which is coupled with proton and/or sodium ion pumping across the membrane. Since no homologous proteins occur in animals and humans, mPPases are good candidates in the design of potential drug targets. Here we present a detailed protocol to screen for mPPase inhibitors utilizing the molybdenum blue reaction in a 96 well plate system. We use mPPase from the thermophilic bacterium *Thermotoga maritima* (TmPPase) as a model enzyme.

This protocol is simple and inexpensive, producing a consistent and robust result. It takes only about one hour to complete the activity assay protocol from the start of the assay until the absorbance measurement. Since the blue color produced in this assay is stable for a long period of time, subsequent assay(s) can be performed immediately after the previous batch, and the absorbance can be measured later for all batches at once. The drawback of this protocol is that it is done manually and thus can be exhausting as well as require good skills of pipetting and time keeping. Furthermore, the arsenite-citrate solution used in this assay contains sodium arsenite, which is toxic and should be handled with necessary precautions.

INTRODUCTION:

Approximately 25% of the total cellular proteins are membrane proteins and about 60% of them are drug targets^{1,2}. One of the potential drug targets³, membrane-bound pyrophosphatases (mPPases), are dimeric enzymes that pump proton and/or sodium ion across the membrane by hydrolysis of pyrophosphate into two orthophosphates⁴. mPPases can be found in various organisms⁵ such as bacteria, archaea, plants, and protist parasites, with the exception of humans and animals⁴. In protist parasites, for example *Plasmodium falciparum, Toxoplasma gondii* and *Trypanosoma brucei*, mPPases are essential for the parasite virulence⁶ and knockout of this expression in the parasites lead to failure in maintaining intracellular pH upon exposure to the external basic pH⁷. Due to their importance and lack of homologous protein present in vertebrates, mPPases can be considered as potential drug targets for protistal diseases³.

The in vitro screening of mPPase inhibitors in this work is based on a TmPPase model system. TmPPase is a sodium ion pumping and potassium ion dependent mPPase from *T. maritima* and has its optimum activity at 71 °C⁸. Benefits of this enzyme are for example its ease in production and purification, good thermal stability and high specific activity. TmPPase shows both high similarity in addition to the complete conservation of the position as well as identity of all catalytic residues to the protist mPPases^{3,9} and to the solved structure of *Vigna radiata*¹⁰ mPPase. The available structures of TmPPase in different conformations are also useful for structure-based drug design experiment (as virtual screening and de novo design).

Here we report a detailed protocol for screening of TmPPase inhibitors in a 96 well plate format (**Figure 1**). The protocol is based on the colorimetric method of the molybdenum blue reaction, which was first developed by Fiske and Subbarow¹¹. This method involves the formation of 12-phosphomolybdic acid from orthophosphate and molybdate under acidic conditions, which is then reduced to give characteristic blue-colored phosphomolybdenum species¹².

PROTOCOL:

1. Protein preparation

NOTE: The expression and purification of TmPPase has been described elsewhere¹³.

1.1. Prepare 10 mL of the reactivation buffer solution containing 20 mM 2-(*N*-morpholino)ethanesulfonic acid (MES) pH 6.5, 3.5% (v/v) glycerol, 2 mM dithiothreitol (DTT), and 0.05% dodecyl maltoside (DDM).

1.2. Prepare 10 mL of the reaction mixture containing 200 mM Tris-Cl pH 8.0, 8.0 mM MgCl₂, 333 mM KCl, and 67 mM NaCl.

NOTE: Mg²⁺ is required to chelate the pyrophosphate as the substrate of mPPase, K⁺ is required to increase the enzyme activity as TmPPase is a potassium dependent mPPase, and Na⁺ is needed for the enzyme activity during sodium ion translocation by TmPPase.

1.3. Prepare 30 mg/mL liposomes for enzyme reactivation.

1.3.1. Add 0.3 g of L- α -phosphatidylcholine from soybean to 10 mL of 20 mM Tris-HCl pH 8.0 with 1 mM DTT.

1.3.2. Sonicate the liposome with 1 s pulse interval for 1 min, pause for 1 min, and repeat until the solution becomes transparent yellow.

1.3.3. Aliquot the liposomes, freeze in liquid nitrogen and store at -80 °C until used.

1.4. Reactivate the enzyme.

1.4.1. Mix 40 μ L of the liposomes solution with 22.5 μ L of 20% DDM.

1.4.2. Heat the mixture at 55 °C for 15 min and allow it to cool to room temperature.

1.4.3. Add 36.5 μ L of the reactivation buffer solution, mix, and add 1 μ L of concentrated protein (13 mg/mL) to make a total concentration of 0.13 mg/mL.

NOTE: Protein is usually frozen in 10 μ L aliquots after purification and thawed on ice before use.

1.5. Take 20 μL of the reactivated enzyme and add to 1,480 μL of the reaction mixture, then mix gently.

NOTE: The addition of the reactivated enzyme to the reaction mixture should be performed just before it is used.

2. Compound preparation

2.1. Dissolve the compounds in dimethyl sulfoxide (DMSO) to make stock solutions of 25–100 mM in 50–200 μ L, based on the availability of the compounds.

NOTE: All compounds used here (**Figure 2A**) have been published previously⁹. If the compound solubility is low, the stock concentration can be adjusted accordingly.

2.2. Prepare three different concentrations of each compound in water.

2.2.1. Dilute the stock solution with water to 1 mL in microtubes to give 2 μ M, 10 μ M and 100 μ M for soluble compounds, or alternatively 2 μ M, 10 μ M and 40 μ M for sparingly soluble compounds.

2.2.2. Vortex the compound solution instantly after dilution of the stock solution for proper mixing.

2.3. Check the possible compound aggregation in the assay using a nephelometer.

NOTE: This was studied as triplicates in three concentrations (1 μ M, 5 μ M and 20 μ M) and normalized to the blank in a 96 well plate.

2.3.1. Dispense 75 μ L of the reaction mixture into each well using a multichannel pipette.

2.3.2. Add 75 μ L of each compound (for the blank, use 75 μ L of water instead) and mix by pipetting up and down 5x.

2.3.3. Measure the turbidity of each well at 300 V using a microplate nephelometer.

3. Reagents for the assay preparation

3.1. Prepare the arsenite-citrate solution.

3.1.1. Weigh 5 g of sodium arsenite and 5 g of trisodium citrate dihydrate.

CAUTION: Sodium arsenite is toxic, thus use proper protective equipment and handle with special care. As precaution, do not handle before all necessary safety precautions have been read and understood. Handle only in a fume hood in order not to inhale dust/vapors of the compound or its solution(s). If inhaled, move to fresh air and obtain medical attention. Wear appropriate chemical safety goggles, protective gloves and clothing to avoid ingestion and eye/skin contact. If swallowed, call immediately a poison center or doctor/physician. If it gets on the skin or in the eye(s), wash with plenty of water and obtain medical attention.

3.1.2. Dissolve into 100 mL of water.

3.1.3. Add 5 mL of glacial acetic acid, mix, and add water to 250 mL.

3.1.4. Store at room temperature protected from light.

NOTE: The solution is stable for more than a year.

3.2. Prepare solution A and solution B.

3.2.1. For solution A, add 10 mL of ice cold 0.5 M HCl to 0.3 g of ascorbic acid. Dissolve the ascorbic acid by vortexing.

3.2.2. For solution B, add 1 mL of ice cold water to 70 mg of ammonium heptamolybdate tetrahydrate and vortex to dissolve.

NOTE: Store both solutions on ice until use. For the consistency of the assay result, both solutions can be stored on ice for a maximum of a week.

3.3. Prepare the phosphate (P_i) standard with the concentration of 0 μ M, 62.5 μ M, 250 μ M and 500 μ M for calibration.

3.3.1. Add 0 μ L, 25 μ L, 50 μ L, and 100 μ L of 5 mM Na_2HPO_4 dihydrate to four microtubes containing 370 μ L of the reaction mixture.

3.3.2. Top up to 1 mL with water.

4. Activity assay for one 96 well plate

NOTE: See **Figure 1** for the schematic workflow of the assay.

4.1. Add 1 mL of solution B to 10 mL of solution A, mix by vortexing and store the solution on ice.

NOTE: This solution should be transparent and yellow. Keep solution A + B on ice for at least 30 min prior to use. However, use the solution within 3 h as it will go bad after long-term storage.

4.2. Add 40 μ L of 0 μ M, 62.5 μ M, 250 μ M and 500 μ M Pi standard to the tube strips in triplicate using a multichannel pipette.

NOTE: The reaction mixture with no Pi added will be used as a blank.

4.3. Add 25 μ L of compound solution to the tube strips using a multichannel pipette.

NOTE: Each compound has three different concentrations in triplicate which is enough for initial estimation of the half maximal inhibitory concentration (IC_{50}). For a more accurate IC_{50} determination, eight different compound concentrations can be used. For the uninhibited enzyme the compound solution is replaced with equal amount of water. As positive controls 2.5 μ M, 25 μ M, and 250 μ M of imidodiphosphate (IDP) sodium salt were used.

4.4. Add 15 μ L of mPPase solution mixture to the tube strips (except to the tubes containing Pi standard) using a multichannel pipette.

4.5. Seal the tube strips with an adhesive sealing sheet. Cut the sealing sheet to separate each tube strip.

4.6. Pre-incubate the samples for 5 min at 71 °C. Place the samples on the heating block with 20 s interval between each strip in order to minimize the time consumption during the subsequent steps.

4.7. For each strip, open the adhesive sealing. Add 10 μ L of 2 mM sodium pyrophosphate dibasic using a multichannel pipette and mix by pipetting up and down for 5x. Seal the tube strip again using the same sealing.

NOTE: This step might initially be difficult to accomplish in 20 s; however, it will become easier after some assays.

4.8. Incubate at 71 °C for 5 min.

4.9. Place the samples on the cooling apparatus with 20 s interval between each strip. Let them cool for 10 min but centrifuge each strip briefly after 5 min of cooling, to decant water drops under the sealing sheet, then put it back to the cooling apparatus and remove the sealing.

NOTE: The cooling apparatus can simply be made by placing a 96 well PCR plate on a polystyrene Petri dish (size 150 mm x 15 mm) filled with water and frozen for at least 1 h. The apparatus should be taken out from the freezer about 5 min prior to the beginning of the assay. Do not take out the cooling apparatus right before sample cooling as it will freeze the reaction mixture and hinder color development.

4.10. After 10 min of cooling, add 60 μ L of solution A + B, mix by pipetting up and down for 5x and keep the tube strips on the cooling apparatus for 10 min.

4.11. Add 90 μ L of the arsenite-citrate solution and keep at room temperature for at least 30 min to produce a stable blue color.

CAUTION: Due to its toxicity all solutions containing sodium arsenite should be handled with extra care at all time. Thus, the addition of arsenite-citrate solution should be done in a fume hood.

4.12. Dispense 180 μ L of each reaction mixture into a clear 96 well polystyrene microplate.

4.13. Measure the absorbance of each well at 860 nm using a microplate spectrophotometer.

5. Result analysis

5.1. Average the triplicates of each sample and the P_i standards. Then subtract with the blank to eliminate the background signal.

5.2. Make a calibration curve by plotting the absorbance (A_{860}) values against the amount of P_i standard (nmol) and perform a linear regression to obtain the trendline function using the following formula:

$$A_{860} = mP_i + b$$

5.3. Calculate the phosphate amount (nmol) released from the enzymatic reaction based on the linear regression formula above.

5.4. Calculate the specific activity using the following formula:

Specific activity (SA) =
$$\frac{nP_i}{t \cdot m_{TmPPase}}$$

where nP_i is the amount of phosphate released from the reaction (nmol), t is the reaction time (min), and $m_{TmPPase}$ is the amount of the pure TmPPase used in the assay (mg).

5.5. Calculate the percent activity for each inhibitor concentration using the following formula:

% Activity =
$$\frac{SA_i}{SA_{un}} \times 100\%$$

where SA_i is the specific activity of a sample with inhibitor and SA_{un} is the specific activity of the uninhibited sample.

5.6. Calculate the $logIC_{50}$ (estimate) and IC_{50} (estimate) with a nonlinear regression fit from the four-parameter dose-response curve using the following formula:

$$Y = Bottom + (Top - Bottom)/(1 + 10^{((logIC_{50} - X)^* HillSlope)})$$

where X is log of concentration (μ M), Y is activity (%), Top and Bottom are plateaus in the same unit as Y (100% and 0%, respectively), logIC₅₀ has the same log units as X, and HillSlope = slope factor or hill slope, which is unitless.

NOTE: Software (**Table of Materials**) is used for the fitting. Use the concentration of 0.01 μ M (instead of 0.00 μ M) for the sample without inhibitor as the logarithm of zero is not defined.

REPRESENTATIVE RESULTS:

In this protocol, eight compounds (1–8) were tested (**Figure 2A**) together with IDP, a common inhibitor of pyrophosphatases, as a positive control. Each compound was tested at three different

concentrations (1 μ M, 5 μ M and 20 μ M) in triplicate. The workflow of the screening is depicted in **Figure 1**, starting from sample and reagent preparation until the absorbance measurement at 860 nm.

At the end of this protocol, after the addition of solution A + B and arsenite-citrate, the solutions develop a stable blue color with the maximum absorption at 709 nm and 860 nm¹⁴ due to the complex formation of phosphate ions with molybdate that can be observed and shows the occurrence of the enzymatic reaction. For this experiment, we use the absorbance at 860 nm for the measurement of Pi amount released as it has better detection limit and sensitivity compared to the absorbance at 709 nm¹⁵. The blue color is fully developed in 30 min of incubation at room temperature and stable for at least 5 h¹⁴. The assay has the sensitivity down to Pi concentration of 10 μ M and the absorbance is linear over a concentration range of 10–800 μ M¹⁴. In the representative result here, wells E1–E3 (Figure 2C) contain the reaction mixture without inhibitor and the blue solution can be observed at the end of the assay. This can also be observed at low compound concentrations where complete inhibition has not been reached, as in wells F1–F3 for IDP and wells A4-A6 for compound 1 (ATC, a recently known uncompetitive inhibitor of TmPPase⁹) at the concentration of 2.5 μ M and 1 μ M, respectively. The higher concentration of IDP and compound 1, the less to no blue color can be observed (G1–G3 and H1–H3 for IDP and B4–B6 and C4–C6 for compound 1) indicating inhibition of the enzymatic activity. All three concentrations of non-inhibiting compounds (2, 3, and 8) displayed the same blue color intensity as wells E1–E3 without any inhibitor (Figure 2C).

After the absorbance measurement at 860 nm, the data can be processed and analyzed (see protocol section 5). **Figure 2D** shows the calibration plot of Pi standard with its linear fitting (y = 0.0576x + 0.0019; $r^2 = 0.999$). **Figure 3** shows the plot of enzymatic activity (%) against the concentration of each tested compound. For compounds with inhibition activity, a nonlinear curve fitting is also shown. IDP, used as a positive control, clearly shows a decrease in activity at higher concentration. The IC₅₀ (estimate) calculated based on three different concentrations is 88.2 μ M (**Table 1**), which is similar to the previous measurement (80.0 μ M) with eight concentration points¹⁴. Compounds **1**, **4**, **5**, **6**, and **7** showed a similar trend as IDP since the concentration increased with the IC₅₀ (estimate) of approximately 1.3 μ M, 7.4 μ M, 19.0 μ M, 37.4 μ M, and 156.1 μ M, respectively (**Table 1**). For compounds **2**, **3**, and **8** no reduction in activity or inhibition can be observed at the assay concentrations. An additional assay with eight concentration points can be done to generate precise IC₅₀. **Figure 4** shows the inhibition curve for compounds **1**, **5**, **6**, **7** and **8** with an IC₅₀ of 1.7 μ M, 21.4 μ M, 58.8 μ M, 239.0 μ M and >500 μ M, respectively⁹.

FIGURE AND TABLE LEGENDS:

Figure 1: A schematic workflow of TmPPase inhibition assay in a 96 well plate format. The red numbering shows the steps of the assay according to the protocol and the blue arrows show the interval order.

Figure 2: Samples, their arrangement and color development in a 96 well plate. (A) The structures of compounds 1–8 used for the assay. The inhibition activity of these compounds has been reported in Vidilaseris et al.⁹. (B) Sample arrangement. (C) Color development, 30 min after the addition of arsenite-citrate solution. The concentrations of control inhibitor (IDP) and samples used, arranged from the top to the bottom, are 2.5 μ M, 25 μ M, and 250 μ M concentration and 1 μ M, 5 μ M, and 20 μ M concentration, respectively. The intensity of the blue color corresponds to the amount of P_i released due to the enzymatic reaction and the lack of color corresponds to no enzymatic reaction. (D) Calibration curve for P_i standard (nmol) against A₈₆₀ with linear fitting (y = 0.0576x + 0.0019; r^2 = 0.999).

Figure 3: Curve of the TmPPase percent activity for three different inhibitor concentrations. The nonlinear regression curves to calculate the IC_{50} (estimate) are shown for IDP as well as for compounds 1, 4, 5, 6 and 7 but not for compounds 2, 3, and 8 as they were not inhibiting TmPPase activity at the assay concentrations. The IO_{50} and IC_{50} (estimate) of each compound is shown in **Table 1**. All data are shown as mean ± SD with three replicates.

Figure 4: Inhibition curve from eight concentration points of compounds 1, 5, 6, 7 and 8. This figure is taken from Vidilaseris et al.⁹ with slight modification. All data are shown as mean ± SD with three replicates.

Table 1: LogIC₅₀ and IC₅₀ (estimate) of IDP and compounds 1–8 based on the data from Figure 3.

DISCUSSION:

Here we report a detailed protocol for simple screening of inhibitors for membrane-bound pyrophosphatase from *T. maritima* in a 96 well plate format based on Vidilaseris et al.¹⁴. This protocol is inexpensive and based on 12-phosphomolybdic acid, which is formed from orthophosphate and molybdate under acidic conditions and reduced to phosphomolybdenum species with a distinct blue color¹². This method is preferred over other protocols, such as the more sensitive malachite green assay¹⁶, because this method does not show interference in the presence of high phospholipid concentration which is required for TmPPase reactivation¹⁴.

The workflow of the screening protocol is depicted in **Figure 1** and this process can be fully accomplished in 1 h. This protocol is optimized for TmPPase with the optimal working temperature at 71 °C and a 5 min reaction time. As water will evaporate at this temperature from the reaction mixture, an adhesive sealing sheet (sliced to fit and cover the strips) is applied to prevent evaporation¹⁴ and the evaporated water is simply recollected with centrifugation. The 5 min incubation time is chosen as it is still in the linear range of the enzymatically released phosphate and sufficient for reliable screening¹⁴. In this protocol, the timing and pipetting skills are important factors to obtain a good and reliable result. Addition of reagents during the assay with 20 s interval between strips is an optimized timing option for ease of performing the subsequent steps.

For different mPPases, the optimum temperature and incubation time should be determined separately prior to use in the inhibition assay. The enzyme reactivation protocol above is optimized for TmPPase and other mPPases might need a different reactivation protocol. For example, DDM should not be added for reactivation of mPPase from *Pyrobaculum aerophilum* as it will decrease its enzymatic activity¹⁷. As the enzyme will become less active if prepared well in advance, the addition of reactivated enzyme should be added to the reaction mixture shortly before the assay is initiated. After addition of the arsenite-citrate solution the reaction product is stable for at least 5 h¹⁴. Therefore, the next batch of the assay can be performed immediately, and the absorbance measurement can be done later to all batches at once.

ACKNOWLEDGMENTS:

This work was supported by the grants from the Jane and Aatos Erkko Foundation and the BBSRC (BB/M021610) to Adrian Goldman, the Academy of Finland (No. 308105) to Keni Vidilaseris, (No. 310297) to Henri Xhaard, and (No. 265481) to Jari Yli-Kauhaluoma, and the University of Helsinki Research Funds to Gustav Boije af Gennäs. The authors thank Bernadette Gehl for her technical help during the project.

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

1. Terstappen, G. C., Reggiani, A. In silico research in drug discovery. *Trends in Pharmacological Sciences.* **22** (1), 23-26 (2001).

2. Rask-Andersen, M., Almen, M. S., Schioth, H. B. Trends in the exploitation of novel drug targets. *Nature Reviews Drug Discovery.* **10** (8), 579-590 (2011).

3. Shah, N. R., Vidilaseris, K., Xhaard, H., Goldman, A. Integral membrane pyrophosphatases: a novel drug target for human pathogens? *AIMS Biophysics.* **3** (1), 171-194 (2016).

4. Baykov, A. A., Malinen, A. M., Luoto, H. H., Lahti, R. Pyrophosphate-Fueled Na⁺ and H⁺ Transport in Prokaryotes. *Microbiology and Molecular Biology Reviews.* **77** (2), 267-276 (2013).

5. Serrano, A., Perez-Castineira, J. R., Baltscheffsky, M., Baltscheffsky, H. H⁺-PPases: yesterday, today and tomorrow. *IUBMB Life*. **59** (2), 76-83 (2007).

6. Liu, J. et al. A vacuolar-H⁺-pyrophosphatase (TgVP1) is required for microneme secretion, host cell invasion, and extracellular survival of *Toxoplasma gondii*. *Molecular Microbiology*. **93** (4), 698-712 (2014).

7. Lemercier, G. et al. A pyrophosphatase regulating polyphosphate metabolism in acidocalcisomes is essential for *Trypanosoma brucei* virulence in mice. *Journal of Biological Chemistry.* **279** (5), 3420-3425 (2004).

8. Belogurov, G. A. et al. Membrane-bound pyrophosphatase of *Thermotoga maritima* requires sodium for activity. *Biochemistry.* **44** (6), 2088-2096 (2005).

9. Vidilaseris, K. et al. Asymmetry in catalysis by *Thermotoga maritima* membrane-bound pyrophosphatase demonstrated by a nonphosphorus allosteric inhibitor. *Science Advances.* **5** (5), eaav7574 (2019).

10. Lin, S.-M. et al. Crystal structure of a membrane-embedded H⁺-translocating pyrophosphatase. *Nature.* **484** (7394), 399-403 (2012).

11. Fiske, C. H., Subbarow, Y. The colorimetric determination of phosphorus. *Journal of Biological Chemistry.* **66** (2), 375-400 (1925).

12. Nagul, E. A., McKelvie, I. D., Worsfold, P., Kolev, S. D. The molybdenum blue reaction for the determination of orthophosphate revisited: Opening the black box. *Analytica Chimica Acta*. **890** 60-82 (2015).

13. Kellosalo, J., Kajander, T., Palmgren, M. G., Lopez-Marques, R. L., Goldman, A. Heterologous expression and purification of membrane-bound pyrophosphatases. *Protein Expression and Purification*. **79** (1), 25-34 (2011).

14. Vidilaseris, K., Kellosalo, J., Goldman, A. A high-throughput method for orthophosphate determination of thermostable membrane-bound pyrophosphatase activity. *Analytical Methods*. **10** (6), 646-651 (2018).

15. He, Z. Q., Honeycutt, C. W. A modified molybdenum blue method for orthophosphate determination suitable for investigating enzymatic hydrolysis of organic phosphates. *Communications in Soil Science and Plant Analysis.* **36** (9-10), 1373-1383 (2005).

16. Martin, B., Pallen, C. J., Wang, J. H., Graves, D. J. Use of fluorinated tyrosine phosphates to probe the substrate specificity of the low molecular weight phosphatase activity of calcineurin. *Journal of Biological Chemistry.* **260** (28), 14932-14937 (1985).

17. Strauss, J., Wilkinson, C., Vidilaseris, K., Harborne, S. P. D., Goldman, A. A simple strategy to determine the dependence of membrane-bound pyrophosphatases on K⁺ as a cofactor. *Methods in Enzymology*. **607**, 131-156 (2018).

Figure 1





Figure 2






Figure 3




Figure 4

